Cargando…
miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR
HCC is a common malignancy worldwide and surgery or reginal treatments are deemed insufficient for advanced-stage disease. Sorafenib is an inhibitor of many kinases and was shown to benefit advanced HCC patients. However, resistance emerges soon after initial treatment, limiting the clinical benefit...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170966/ https://www.ncbi.nlm.nih.gov/pubmed/32313144 http://dx.doi.org/10.1038/s41419-020-2413-4 |